# Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00099125** · PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 170 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** irinotecan hydrochloride
- **DRUG:** temozolomide
- **PROCEDURE:** adjuvant therapy
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00099125
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-10
- **Final completion:** 2013-11
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2014-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099125, "Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00099125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*